Abstract:The Wnt/β-catenin pathway is constitutively active and promotes multiple tumor processes, including breast cancer metastasis. However, the underlying mechanism by which the Wnt/β-catenin pathway is constitutively activated in breast cancer metastasis remains unclear. Inhibition of Wnt antagonists is important for Wnt/β-catenin signaling activation, and post-transcriptional regulation of these antagonists by microRNAs (miRNAs) might be a possible mechanism underlying signaling activation. Regulation of nuclear pre-mRNA domain-containing 1A (RPRD1A) is a known inhibitor of cell growth and Wnt/β-catenin signaling activity, but the function and regulatory mechanism of RPRD1A in breast cancer have not been clarified. The aim of this study was to understand how regulators of the Wnt/β-catenin pathway may play a role in the metastasis of this cancer. Methods: RPRD1A expression and its association with multiple clinicopathological characteristics was analyzed immunohistochemically in human breast cancer specimens. miR-454-3p expression was analyzed using real-time PCR. RPRD1A or miR-454-3p knockdown and overexpression were used to determine the underlying mechanism of their functions in breast cancer cells. Xenografted tumor model, 3D invasive culture, cell migration and invasion assays and sphere formation assay were used to determine the biofunction of RPRD1A and miR-454-3p in breast cancer. Electrophoretic mobility shift assay (EMSA), luciferase reporter assay, and RNA immunoprecipitation (RIP) were performed to study the regulation and underlying mechanisms of RPRD1A and miR-454-3p expression and their correlation with the Wnt/β-catenin pathway in breast cancer. Results: The Wnt/β-catenin signaling antagonist RPRD1A was downregulated and its upstream regulator miR-454-3p was amplified and overexpressed in metastatic breast cancer, and both were correlated with overall and relapse-free survival in breast cancer patients. The suppression by miR-454-3p on RPRD1A was found to activate Wnt/β-catenin signaling, thereby promoting metastasis. Simultaneously, three other negative regulators of the Wnt/β-catenin pathway, namely, AXIN2, dickkopf WNT signaling pathway inhibitor (DKK) 3 and secreted frizzled related protein (SFRP) 1, were also found to be targets of miR-454-3p and were involved in the signaling activation. miR-454-3p was found to be involved in early metastatic processes and to promote the stemness of breast cancer cells and early relapse under both in vitro and in vivo conditions. Conclusions: The findings indicate that miR-454-3p-mediated suppression of Wnt/β-catenin antagonist RPRD1A, as well as AXIN2, DKK3 and SFRP1, sustains the constitutive activation of Wnt/β-catenin signaling; thus, miR-454-3p and RPRD1A might be potential diagnostic and therapeutic targets for breast cancer metastasis.

RETRACTION: MiR-370-5p Inhibits the Progression of Breast Cancer Via Targeting LUC7L3 (retraction of Vol 41, Pg 442, 2021)

RETRACTED ARTICLE: MiR-370-5p Inhibits the Progression of Breast Cancer Via Targeting LUC7L3

RETRACTED: MicroRNA-181 Serves an Oncogenic Role in Breast Cancer Via the Inhibition of SPRY4 (retracted Article. See Vol. 25, 2022)

MicroRNA-3613-3p Functions As a Tumor Suppressor and Represents a Novel Therapeutic Target in Breast Cancer.

MiR-454-3p-Mediated Wnt/β-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis

Downregulated Mir-1247-5p Associates with Poor Prognosis and Facilitates Tumor Cell Growth Via DVL1/Wnt/β-catenin Signaling in Breast Cancer

RETRACTION: microRNA-485 inhibits the malignant behaviors of retinoblastoma by directly targeting Wnt3a (Retraction of Vol 41, Pg 3137, 2019)

Microrna-34a Suppresses Cell Proliferation by Targeting Lmtk3 in Human Breast Cancer Mcf-7 Cell Line

RETRACTED ARTICLE: MiR-140-5p Inhibits Cell Proliferation and Metastasis by Regulating MUC1 Via BCL2A1/MAPK Pathway in Triple Negative Breast Cancer

MiR-34a Inhibits Proliferation and Migration of Breast Cancer Through Down-Regulation of Bcl-2 and SIRT1

MicroRNA-409-5p is Upregulated in Breast Cancer and Its Downregulation Inhibits Cancer Development Through Downstream Target of RSU1

Mir-143-3p Targeting LIM Domain Kinase 1 Suppresses the Progression of Triple-Negative Breast Cancer Cells.

Retracted: Microrna-4656 Is A Prognostic Factor And Tumor Suppressor In Human Pancreatic Cancer Through A Downstream Target Of Trka (Retracted Article. See Vol 19, Artn E2967, 2017)

Retracted: Mir-126 Inhibits Papillary Thyroid Carcinoma Growth By Targeting Lrp6 (Retracted Article. See Vol. 46, Pg. 146, 2021)

RETRACTED: MicroRNA-936 inhibits the malignant phenotype of retinoblastoma by directly targeting <i>HDAC9</i> and deactivating the PI3K/AKT pathway (Retracted article. See vol. 48, 2022)

MicroRNA-34a Suppresses Breast Cancer Cell Proliferation and Invasion by Targeting Notch1

Mir-3646 Promotes Cell Proliferation, Migration, and Invasion Via Regulating G2/M Transition in Human Breast Cancer Cells.

RETRACTED: MicroRNA-361-5p Inhibits Papillary Thyroid Carcinoma Progression by Targeting ROCK1

RETRACTED: MicroRNA-4268 inhibits cell proliferation via AKT/JNK signalling pathways by targeting Rab6B in human gastric cancer (Retracted article. See AUG, 2023)

RETRACTED: MicroRNA-873 Inhibits the Proliferation and Invasion of Endometrial Cancer Cells by Directly Targeting Hepatoma-Derived Growth Factor (retracted Article. See Vol. 24, 2022)

RETRACTED: A Pleiotropically Acting MicroRNA, Mir-31, Inhibits Breast Cancer Metastasis